Tom Ognar, portfolio manager with the Heritage Growth Team, explains how they’re finding growth opportunities in a rising market environment.
“…knolege [sic] is power and ignorance is weakness.” —Thomas Jefferson
“Surprise, surprise, surprise.”—Gomer Pyle USMC
“Don’t take it serious, it’s too mysterious.” –Life is Just a Bowl of Cherries, lyrics by Lew Brown
“Prophecy is the most gratuitous form of error.” –George Eliot
John Manley, Chief Equity Strategist with Wells Fargo Asset Management, joins us to take stock of the equity markets.
“…there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns – the ones we don’t know we don’t know…it is the latter category that tend to be the difficult ones.” –United States Secretary of Defense Donald Rumsfeld
Last week, U.S. stocks rose on reports that the new administration might lower corporate tax rates.
The old adage had its day—but not today. Dr. Brian Jacobsen dispels the myth and offers investors a better approach.
John Manley and Jim Kochan discuss the current state of the equity and fixed-income markets.
“… what mighty contests spring from trivial things …” —Alexander Pope
“There’s many a slip ‘twixt the cup and the lip.” —English proverb
I’d like to make a few observations on two things I noticed last week.
First, bottom-up consensus forward earnings expectations slipped last week, and that is not a good thing. However, it’s not exactly bad either. The number declined only about $0.07 per share. Still, the movement is in the wrong direction, and most of the decline was caused by reductions in 2016 expectations. There are still no blatant signs of an economic meltdown, so I remain skeptical of a violent slowdown but vigilant for its early indicators.
Second, the biotech group was hard-hit during the week. The most given reason and the probable cause were comments by Hillary Clinton about a steep price increase in the cost of a certain HIV drug. Given the very high valuations placed on many companies in the biotech space, the decline was not unreasonable, in my opinion. Very little is needed to knock extended equities down.